CY1119324T1 - Αντισωματα εναντιον csf-1r - Google Patents

Αντισωματα εναντιον csf-1r

Info

Publication number
CY1119324T1
CY1119324T1 CY20171100949T CY171100949T CY1119324T1 CY 1119324 T1 CY1119324 T1 CY 1119324T1 CY 20171100949 T CY20171100949 T CY 20171100949T CY 171100949 T CY171100949 T CY 171100949T CY 1119324 T1 CY1119324 T1 CY 1119324T1
Authority
CY
Cyprus
Prior art keywords
1r
csf
antibodies
inducing
invention
Prior art date
Application number
CY20171100949T
Other languages
English (en)
Inventor
Jacqueline Francoise Doody
Yanxia Li
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US31989610P priority Critical
Priority to PCT/US2011/030148 priority patent/WO2011123381A1/en
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of CY1119324T1 publication Critical patent/CY1119324T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η εφεύρεση παρέχει ανθρώπινο αντίσωμα που δεσμεύεται με ανθρώπινο CSF-1R με υψηλή συγγένεια. Τα αντισώματα της παρούσας εφεύρεσης έχουν σημαντικά πλεονεκτήματα συγκριτικά με τα αντισώματα που είναι γνωστά στην τεχνολογία όντας πολυλειτουργικά: αναστέλλοντας σηματοδότηση του CSF-1R, εσωτερικευόμενα και επάγοντας αποικοδόμηση CSF-1R και διεγείροντας ADCC σε κύτταρα που περιλαμβάνουν όγκους, μακροφάγα και μονοκύτταρα. Επιδεικνύεται επίσης ότι είναι αποτελεσματικά σε θεραπευτική αγωγή λευχαιμίας, καρκίνου μαστού, ενδομητρίου και προστάτη, μόνα τους ή σε συνδυασμό με δοκεταξέλη, πακλιταξέλη, Herceptin® ή δοξορουβικίνη.
CY20171100949T 2010-04-01 2017-09-07 Αντισωματα εναντιον csf-1r CY1119324T1 (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US31989610P true 2010-04-01 2010-04-01
PCT/US2011/030148 WO2011123381A1 (en) 2010-04-01 2011-03-28 Antibodies against csf-1r

Publications (1)

Publication Number Publication Date
CY1119324T1 true CY1119324T1 (el) 2018-02-14

Family

ID=44010222

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100949T CY1119324T1 (el) 2010-04-01 2017-09-07 Αντισωματα εναντιον csf-1r

Country Status (30)

Country Link
US (1) US8263079B2 (el)
EP (2) EP3156419A1 (el)
JP (1) JP5767310B2 (el)
KR (1) KR101439719B1 (el)
CN (1) CN102834414B (el)
AR (1) AR080698A1 (el)
AU (1) AU2011232850B2 (el)
BR (1) BR112012024564A2 (el)
CA (1) CA2795081C (el)
CY (1) CY1119324T1 (el)
DK (1) DK2552966T3 (el)
EA (1) EA021600B1 (el)
ES (1) ES2640909T3 (el)
HR (1) HRP20171153T1 (el)
HU (1) HUE036379T2 (el)
IL (1) IL222222A (el)
JO (1) JO3291B1 (el)
LT (1) LT2552966T (el)
ME (1) ME02806B (el)
MX (1) MX2012011234A (el)
NZ (1) NZ602621A (el)
PL (1) PL2552966T3 (el)
PT (1) PT2552966T (el)
RS (1) RS56219B1 (el)
SG (1) SG183829A1 (el)
SI (1) SI2552966T1 (el)
TW (1) TWI402078B (el)
UA (1) UA111818C2 (el)
WO (1) WO2011123381A1 (el)
ZA (1) ZA201206926B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791738B (zh) 2009-12-10 2015-10-07 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
TWI651331B (zh) 2010-05-04 2019-02-21 戊瑞治療有限公司 與集落刺激因子1受體(csf1r)結合之抗體類
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
JP6416630B2 (ja) * 2012-02-06 2018-10-31 ジェネンテック, インコーポレイテッド Csf1r阻害剤を用いるための組成物及び方法
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015533787A (ja) 2012-08-31 2015-11-26 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子1受容体(csf1r)を結合する抗体によって状態を治療する方法
AR095882A1 (es) 2013-04-22 2015-11-18 F Hoffmann-La Roche Ag Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) * 2013-09-12 2016-03-23 F Hoffmann-La Roche Ag Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR102000224B1 (ko) * 2014-02-03 2019-07-16 전대연 스마트 이메일 관리방법
AU2015339306A1 (en) 2014-10-29 2017-04-20 Bristol-Myers Squibb Company Combination therapy for cancer
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
EP3303390A1 (en) 2015-05-27 2018-04-11 UCB Biopharma SPRL Method for the treatment of neurological disease
JP2017007956A (ja) * 2015-06-17 2017-01-12 研一郎 清野 治療耐性がんに対する治療耐性低減剤
EP3108897A1 (en) * 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
AU2016282877A1 (en) * 2015-06-24 2018-01-04 F. Hoffmann-La Roche Ag Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
WO2017085566A1 (en) * 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
CN108350080A (zh) 2015-11-24 2018-07-31 伊莱利利公司 用于癌症的联合疗法
EP3426265A4 (en) 2016-04-28 2019-09-11 Alkahest Inc Blood plasma and plasma fractions as therapy for tumor growth and progression
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
TW201825519A (zh) 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
EP3558360A1 (en) 2016-12-22 2019-10-30 H. Hoffnabb-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018144334A1 (en) 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
AU2018256406A1 (en) 2017-04-19 2019-10-17 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018200560A1 (en) 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
TW201920279A (zh) 2017-08-25 2019-06-01 美商戊瑞治療有限公司 B7-h4抗體及其使用方法
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN108948201B (zh) * 2018-07-18 2019-05-07 博奥信生物技术(南京)有限公司 抗人csf-1r单克隆抗体及应用
CN108948200B (zh) * 2018-07-18 2019-05-10 博奥信生物技术(南京)有限公司 一种抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术(南京)有限公司 一种抗人csf-1r单克隆抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489D0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1989009825A1 (en) 1988-04-16 1989-10-19 Celltech Limited Method for producing recombinant dna proteins
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
AU2003291002A1 (en) * 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
ES2707284T3 (es) 2005-03-08 2019-04-03 Pfizer Prod Inc Composiciones de anticuerpo anti-CTLA-4
HUE037265T2 (hu) * 2007-08-21 2018-08-28 Amgen Inc Humán c-fms antigént kötõ proteinek
CA2718499C (en) 2008-03-14 2019-06-11 Helene Haegel Antibody against the csf-1r

Also Published As

Publication number Publication date
DK2552966T3 (en) 2017-08-14
KR101439719B1 (ko) 2014-09-12
TWI402078B (zh) 2013-07-21
JP5767310B2 (ja) 2015-08-19
KR20130001258A (ko) 2013-01-03
EP3156419A1 (en) 2017-04-19
TW201138824A (en) 2011-11-16
PT2552966T (pt) 2017-09-29
JO3291B1 (ar) 2018-09-16
MX2012011234A (es) 2012-11-30
ME02806B (me) 2018-01-20
EP2552966B1 (en) 2017-07-05
HRP20171153T1 (hr) 2017-10-06
CN102834414A (zh) 2012-12-19
RS56219B1 (sr) 2017-11-30
EA201270732A1 (ru) 2013-01-30
US8263079B2 (en) 2012-09-11
IL222222D0 (en) 2012-12-31
LT2552966T (lt) 2017-10-10
HUE036379T2 (hu) 2018-07-30
AU2011232850A1 (en) 2012-09-06
CN102834414B (zh) 2014-10-08
US20110243947A1 (en) 2011-10-06
SI2552966T1 (sl) 2017-08-31
CA2795081A1 (en) 2011-10-06
BR112012024564A2 (pt) 2016-11-29
ES2640909T3 (es) 2017-11-07
WO2011123381A1 (en) 2011-10-06
ZA201206926B (en) 2014-03-26
JP2013529183A (ja) 2013-07-18
EA021600B1 (ru) 2015-07-30
UA111818C2 (uk) 2016-06-24
NZ602621A (en) 2014-02-28
CA2795081C (en) 2017-12-05
AU2011232850B2 (en) 2014-06-19
SG183829A1 (en) 2012-10-30
EP2552966A1 (en) 2013-02-06
PL2552966T3 (pl) 2017-12-29
IL222222A (en) 2016-02-29
AR080698A1 (es) 2012-05-02

Similar Documents

Publication Publication Date Title
JO3097B1 (ar) الأجسام المضادة c-Met
CY1117372T1 (el) Υποκατεστημενεσ 5-φθορο-1η-πυραζολοπυριδινεσ και η χρηση τουσ
CY1119006T1 (el) Ινδολια
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
MX2011000236A (es) Agentes de union a notch y antagonistas y metodos de uso de los mismos.
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
CY1112513T1 (xx) Αναστολεισ τησ κινασησ τυροσινησ του bruton
CY1116728T1 (el) Παραγοντεσ οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
PE20121024A1 (es) Moleculas de union biespecificas para la terapia antigiogenesis
CY1113160T1 (xx) Ενωσεισ αρυλουριασ εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CO6430487A2 (es) Anticuerpos anti-her
UY33619A (es) Analogos de nucleotidos sustituidos
AR092612A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos
CY1120102T1 (el) Συνθεσεισ και μεθοδοι για μειωση τριγλυκεριδιων χωρισ αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονησ θεραπειασ στατινησ
UA116192C2 (uk) Активуюча т-клітини біоспецифічна антигензв'язуюча молекула
UA111711C2 (uk) Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
MX2012010115A (es) Compuestos para el tratamiento de cancer.
CL2013000722A1 (es) Compuestos derivados de eteno sustituidos con 3 anillos, o un n-oxido o una sal del mismo, moduladores de receptores de estrogenos; composicion farmaceutica; y su uso para el tratamiento del cancer tal como el cancer de mama y de prostata, migraña, artritis, obesidad, alzheimer, parkinson y psicosis, entre otras enfermedades.
CY1118702T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκουσ και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματοσ (glioblastoma, gbm) και αλλων μορφων καρκινου
DOP2012000240A (es) Proteínas terapéuticas de unión a dll4
BRPI0915660A2 (pt) antagonistas específicos do receptor fgf-r4